CN104415325A - 一种重组人干扰素β-1b冻干制剂及其制备方法 - Google Patents
一种重组人干扰素β-1b冻干制剂及其制备方法 Download PDFInfo
- Publication number
- CN104415325A CN104415325A CN201310377609.6A CN201310377609A CN104415325A CN 104415325 A CN104415325 A CN 104415325A CN 201310377609 A CN201310377609 A CN 201310377609A CN 104415325 A CN104415325 A CN 104415325A
- Authority
- CN
- China
- Prior art keywords
- preparation
- interferon
- desalination
- concentration
- sds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 44
- 108010005714 Interferon beta-1b Proteins 0.000 title claims abstract description 25
- 229960003161 interferon beta-1b Drugs 0.000 title claims abstract description 23
- 102000009027 Albumins Human genes 0.000 claims abstract description 3
- 108010088751 Albumins Proteins 0.000 claims abstract description 3
- 108010050904 Interferons Proteins 0.000 claims description 58
- 102000014150 Interferons Human genes 0.000 claims description 55
- 229940079322 interferon Drugs 0.000 claims description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 32
- 238000010612 desalination reaction Methods 0.000 claims description 31
- 238000009472 formulation Methods 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 21
- 239000011550 stock solution Substances 0.000 claims description 21
- 238000004108 freeze drying Methods 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 20
- 229920005654 Sephadex Polymers 0.000 claims description 13
- 239000012507 Sephadex™ Substances 0.000 claims description 13
- 239000011265 semifinished product Substances 0.000 claims description 12
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 10
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 10
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 238000000108 ultra-filtration Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 8
- 239000007853 buffer solution Substances 0.000 claims description 8
- 239000008363 phosphate buffer Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 238000011068 loading method Methods 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 238000005374 membrane filtration Methods 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 3
- 238000012423 maintenance Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000002953 phosphate buffered saline Substances 0.000 claims description 3
- 230000000630 rising effect Effects 0.000 claims description 3
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 claims description 2
- 239000012506 Sephacryl® Substances 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 102000055647 human CSF2RB Human genes 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 238000005498 polishing Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000012460 protein solution Substances 0.000 claims description 2
- 238000004153 renaturation Methods 0.000 claims description 2
- 239000012537 formulation buffer Substances 0.000 claims 1
- 238000011022 operating instruction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 36
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000008055 phosphate buffer solution Substances 0.000 abstract description 3
- 238000009777 vacuum freeze-drying Methods 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 35
- 239000000047 product Substances 0.000 description 15
- 108090000467 Interferon-beta Proteins 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 102100026720 Interferon beta Human genes 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000000087 stabilizing effect Effects 0.000 description 5
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102000003996 Interferon-beta Human genes 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000010413 mother solution Substances 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940021459 betaseron Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical class CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101710091977 Hydrophobin Proteins 0.000 description 1
- -1 IFN-ω at present Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical class CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 108700027921 interferon tau Proteins 0.000 description 1
- 229940028894 interferon type ii Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000000352 supercritical drying Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012485 toluene extract Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
样品名称 | SDS浓度(g/L) | A499(Au) |
标曲0 | 0 | 0 |
标曲0.005 | 0.005 | 0.014 |
标曲0.01 | 0.01 | 0.033 |
标曲0.02 | 0.02 | 0.047 |
标曲0.03 | 0.03 | 0.062 |
标曲0.04 | 0.04 | 0.075 |
样品名称 | A499(Au) | SDS浓度(g/L) |
101227原液 | 0.039 | 0.0109 |
101230原液 | 0.041 | 0.0115 |
101231原液 | 0.029 | 0.0076 |
101227制剂 | 0.022 | 0.0053 |
101230制剂 | 0.029 | 0.0076 |
101231制剂 | 0.015 | 0.0029 |
批号 | 纯化来源 | 25℃比活IU/mg | 25℃室温存放后复测IU/mg |
080715 | C4 | 3.3×107 | 2.2×107(5months) |
080722 | C4 | 2.3×107 | 3.0×107(4months) |
081006 | SOURCE15 | 3.9×107 | 3.1×107(1week) |
081006 | SOURCE30 | 4.3×107 | 3.1×107(1week) |
081203 | SOURCE15 | 3.1×107 | 2.7×107(1week) |
081222 | SOURCE15 | 28×107 | 29×107(1week) |
检测项目 | 0月 | 1月 | 2月 | 3月 | 6月 |
效价 | 3.89E+07 | 3.17E+07 | 3.38E+07 | 3.28E+07 | 2.86E+07 |
鉴别 | 阳性 | — | — | — | 阳性 |
可见异物 | 合格 | 合格 | 合格 | 合格 | 合格 |
水分 | 1.260% | 2.269% | 2.642% | 2.898% | 1.600% |
PH/外观 | 7.24 | 7.24 | 7.22 | 6.99 | 7.10 |
内毒素 | 合格 | 合格 | 合格 | 合格 | 合格 |
异常毒性 | 合格 | — | — | — | |
多聚体/HPLC | 2.249 | 2.321 | 2.250 | 2.198 | 1.261 |
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310377609.6A CN104415325A (zh) | 2013-08-27 | 2013-08-27 | 一种重组人干扰素β-1b冻干制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310377609.6A CN104415325A (zh) | 2013-08-27 | 2013-08-27 | 一种重组人干扰素β-1b冻干制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104415325A true CN104415325A (zh) | 2015-03-18 |
Family
ID=52966146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310377609.6A Pending CN104415325A (zh) | 2013-08-27 | 2013-08-27 | 一种重组人干扰素β-1b冻干制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104415325A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105310988A (zh) * | 2015-11-23 | 2016-02-10 | 哈药集团生物工程有限公司 | 一种含有重组人干扰素α2b的冻干药物组合物 |
CN107099569A (zh) * | 2017-06-30 | 2017-08-29 | 北京北生研生物制品有限公司 | 一种规模化发酵生产重组人干扰素β1b蛋白的方法 |
CN110426513A (zh) * | 2019-05-23 | 2019-11-08 | 武汉三鹰生物技术有限公司 | 一种无外源蛋白干扰的elisa标准品的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1579545A (zh) * | 2003-08-13 | 2005-02-16 | 北京金赛狮生物制药技术开发有限公司 | 重组人干扰素β-1b用于制备预防、治疗SARS药物中的用途 |
EP2537527A2 (en) * | 2005-03-09 | 2012-12-26 | Guangwen Wei | Uses of recombinant super-compound interferons |
-
2013
- 2013-08-27 CN CN201310377609.6A patent/CN104415325A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1579545A (zh) * | 2003-08-13 | 2005-02-16 | 北京金赛狮生物制药技术开发有限公司 | 重组人干扰素β-1b用于制备预防、治疗SARS药物中的用途 |
EP2537527A2 (en) * | 2005-03-09 | 2012-12-26 | Guangwen Wei | Uses of recombinant super-compound interferons |
Non-Patent Citations (1)
Title |
---|
魏双施等: "重组鸡IFN-α的高效表达与一步复性和纯化", 《中国兽医科学》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105310988A (zh) * | 2015-11-23 | 2016-02-10 | 哈药集团生物工程有限公司 | 一种含有重组人干扰素α2b的冻干药物组合物 |
CN105310988B (zh) * | 2015-11-23 | 2018-05-04 | 哈药集团生物工程有限公司 | 一种含有重组人干扰素α2b的冻干药物组合物 |
CN107099569A (zh) * | 2017-06-30 | 2017-08-29 | 北京北生研生物制品有限公司 | 一种规模化发酵生产重组人干扰素β1b蛋白的方法 |
CN110426513A (zh) * | 2019-05-23 | 2019-11-08 | 武汉三鹰生物技术有限公司 | 一种无外源蛋白干扰的elisa标准品的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090123424A1 (en) | Methods of protein purification and recovery | |
JPH0533208B2 (zh) | ||
CN101143894A (zh) | 高效抑制血管生成多肽及其物理化学修饰方法和应用 | |
CN108524929A (zh) | 一种狂犬病疫苗的生产方法 | |
CN104415325A (zh) | 一种重组人干扰素β-1b冻干制剂及其制备方法 | |
CN102925403A (zh) | 一种能够表达金针菇免疫调节蛋白的重组菌株及其构建方法、蛋白表达纯化方法和蛋白应用 | |
CN113117071B (zh) | 一种无糖基化抗pd-1单克隆抗体的冻干制剂 | |
CN1749274B (zh) | 一种新的重组人干扰素α2b的分离纯化方法 | |
RU2054044C1 (ru) | Способ получения рекомбинантного человеческого свободного от метионина на n-конце гамма-интерферона | |
CN101224296A (zh) | 一种稳定的重组人血管内皮抑制素制剂及其制备工艺 | |
CN102138908A (zh) | 一种注射用胸腺五肽冻干粉针及其制备工艺 | |
KR940010024B1 (ko) | α-인터페론의 제조 및 정제 방법 | |
CN116077649A (zh) | 一种含抗Blys单克隆抗体冻干制剂及其制备工艺 | |
JPH0725898A (ja) | 均質ヒト免疫インターフェロンサブタイプ26k及びその製造法 | |
EP0301314B1 (en) | A method for the purification of interferon | |
CN100355784C (zh) | 聚乙二醇修饰α-干扰素1b的制备方法 | |
CN103432569B (zh) | 重组人血清白蛋白-干扰素α融合蛋白的水溶液及其制备方法 | |
JP2002516087A (ja) | 幾つかの重篤な疾患の治療のための医薬組成物を調製するための修飾されたリゾチームcの使用 | |
CN103408625A (zh) | 一种纯化dna的方法 | |
MIYATA et al. | Pruification of Natural Human Interferon-Gamma by Antibody Affinity Chromatography: Analysis of Constituent Protein Species in the Dimers | |
CN102058546A (zh) | 一种重组猪α-干扰素的冻干制剂及其制备方法和用途 | |
CN109535247A (zh) | 聚乙二醇修饰的藻蓝蛋白及其制备方法与制药应用 | |
Johnston et al. | Factors influencing production of interferon by human lymphoblastoid cells | |
Basso et al. | Biopharmaceuticals and biosimilars | |
CN104056247B (zh) | 一种含有促肝细胞生长素的药物组合物及其制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Applicant after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Applicant before: Tasly Pharmaceutical Group Co., Ltd. |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190505 Address after: 201203 No. 1 and No. 2 Juli Road, China (Shanghai) Free Trade Pilot Area, Pudong New Area, Shanghai Applicant after: Tian Shi Li biological medicine Limited by Share Ltd Address before: 300410 Tianjin Beichen District Huaihe road and Ting Jiang West Road intersection heaven proud of the park Legal Center Intellectual Property Department Applicant before: Tasly Pharmaceutical Group Limited by Share Ltd |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150318 |
|
RJ01 | Rejection of invention patent application after publication |